LENZ BRIAN 4

Accession 0001140361-23-040321

CIK 0001368514other

View on SEC.gov Company Profile

Filed

Aug 16, 8:00 PM ET

Accepted

Aug 17, 9:30 PM ET

Size

32.2 KB

Accession

0001140361-23-040321

Insider Transaction Report

Form 4

Period: 2023-08-15

ADMA BIOLOGICS, INC.ADMA

LENZ BRIAN

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
2023-08-15$3.22/sh+200,000$644,000→ 1,248,803 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-08-15$1.67/sh−97,395$162,650→ 177,605 total
Exercise: $1.67Exp: 2032-03-07→ Common Stock (97,395 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2023-08-15$2.35/sh−83,979$197,351→ 55,021 total
Exercise: $2.35Exp: 2031-02-25→ Common Stock (83,979 underlying)
Sale
Common Stock
2023-08-15$4.60/sh−211,578$972,730→ 782,013 total
Exercise/Conversion
Common Stock
2023-08-15$2.92/sh+85,416$249,415→ 1,048,803 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-08-15$2.92/sh−85,416$249,415→ 14,584 total
Exercise: $2.92Exp: 2030-02-28→ Common Stock (85,416 underlying)
Sale
Common Stock
2023-08-16$4.45/sh−178,184$793,400→ 782,013 total
Exercise/Conversion
Common Stock
2023-08-15$1.67/sh+97,395$162,650→ 879,408 total
Exercise/Conversion
Common Stock
2023-08-15$2.35/sh+83,979$197,351→ 963,387 total
Exercise/Conversion
Common Stock
2023-08-15$3.71/sh+150,000$556,500→ 1,398,803 total
Tax Payment
Common Stock
2023-08-15$4.61/sh−631,078$2,909,270→ 960,197 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-08-15$3.71/sh−150,000$556,500→ 0 total
Exercise: $3.71Exp: 2028-02-09→ Common Stock (150,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2023-08-15$3.66/sh−192,472$704,448→ 0 total
Exercise: $3.66Exp: 2027-06-06→ Common Stock (192,472 underlying)
Exercise/Conversion
Common Stock
2023-08-15$3.66/sh+192,472$704,448→ 1,591,275 total
Exercise/Conversion
Stock Option (Right to Buy)
2023-08-15$3.22/sh−200,000$644,000→ 0 total
Exercise: $3.22Exp: 2029-01-23→ Common Stock (200,000 underlying)

Footnotes (11)

[F1]Reflects the weighted average price of sales on August 15, 2023. The shares were sold in multiple transactions at prices ranging from $4.60 to $4.65, inclusive.
[F10]The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022.
[F11]The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021.
[F2]Reflects the weighted average price of sales on August 16, 2023. The shares were sold in multiple transactions at prices ranging from $4.40 to $4.535, inclusive.
[F3]Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 185,625 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;
[F4](continued from footnote 3) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;
[F5](continued from footnote 4) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 317,608 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
[F6]The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 7, 2026.
[F7]The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025.
[F8]The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024.
[F9]The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023.

Documents

1 file

4
form4.xmlPrimary

Issuer

ADMA BIOLOGICS, INC.

CIK 0001368514

→

Entity typeother

Related Parties

filerCIK 0001283260

Filing Metadata

Form type: 4
Filed: Aug 16, 8:00 PM ET
Accepted: Aug 17, 9:30 PM ET
Size: 32.2 KB

View on SEC.gov